Phase I
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
It was a busy week for clinical trial announcements. Here’s a look.
Codagenix is entering the vaccine arena with a possible new frontrunner in protection: CoviLiv. It’s an intranasal COVID vaccine that provides hope against subvariants.
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
Moderna announced that the first participant has been dosed in a Phase I trial of its HIV trimer mRNA vaccine, mRNA-1574.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
PRESS RELEASES